

# Iart Luca Shytaj

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7171573/publications.pdf>

Version: 2024-02-01

15  
papers

534  
citations

858243

12  
h-index

1113639

15  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1288  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. <i>AIDS Research and Therapy</i> , 2022, 19, 2.	0.7	3
2	The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication <i>in Vitro</i> and Decreases Viral Titers and Disease Progression in Syrian Hamsters. <i>MBio</i> , 2022, 13, e0370521.	1.8	22
3	Glycolysis downregulation is a hallmark of HIV-1 latency and sensitizes infected cells to oxidative stress. <i>EMBO Molecular Medicine</i> , 2021, 13, e13901.	3.3	30
4	NHC-gold compounds mediate immune suppression through induction of AHR-TGF $\beta$ 1 signalling <i>in vitro</i> and in scurfy mice. <i>Communications Biology</i> , 2020, 3, 10.	2.0	14
5	Alterations of redox and iron metabolism accompany the development of HIV-1 latency. <i>EMBO Journal</i> , 2020, 39, e102209.	3.5	37
6	Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 592-600.	1.1	29
7	Multifunctional Roles of the N-Terminal Region of HIV-1 SF2 Nef Are Mediated by Three Independent Protein Interaction Sites. <i>Journal of Virology</i> , 2019, 94, .	1.5	17
8	Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. <i>Journal of Clinical Investigation</i> , 2016, 126, 1630-1639.	3.9	139
9	Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. <i>Retrovirology</i> , 2015, 12, 51.	0.9	48
10	Cell-mediated anti-Gag immunity in pharmacologically induced functional cure of simian AIDS: a "bottleneck effect"? <i>Journal of Medical Primatology</i> , 2015, 44, 227-240.	0.3	4
11	Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. <i>Journal of Virology</i> , 2015, 89, 7521-7535.	1.5	20
12	Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. <i>Retrovirology</i> , 2013, 10, 71.	0.9	30
13	A cure for AIDS: a matter of timing?. <i>Retrovirology</i> , 2013, 10, 145.	0.9	11
14	A candidate anti-HIV reservoir compound, auranofin, exerts a selective "anti-memory" effect by exploiting the baseline oxidative status of lymphocytes. <i>Cell Death and Disease</i> , 2013, 4, e944-e944.	2.7	49
15	A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model. <i>PLoS Pathogens</i> , 2012, 8, e1002774.	2.1	70